°Á¤Çö(Kang Jeong-Hyun) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
¹ÚÁؼº(Park Joon-Seong) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
¾È¼º±Í(Ahn Sung-Gwe) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
ÀÓÁøÈ«(Lim Jin-Hong) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
¹é½ÂÇõ(Baik Seung-Hyuk) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
À±µ¿¼·(Yoon Dong-Sup) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
ÀÌ°¿µ(Lee Kang-Young) - Yonsei University College of Medicine Severance Hospital Department of Surgery
Á¤ÁØ(Jeong Joon) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Surgery
Abstract
Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer.
Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume).
Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0?2.8] in KRG group vs. median, 1.89 [range, 1.1?3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis.
Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.
Å°¿öµå
Oxaliplatin, Splenomegaly, Colonic neoplasms, Folfox protocol
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly.